51 results about "Levocetirizine hydrochloride" patented technology

A solid oral dosage composition is provided comprising a prophilactically or therapeutically effective amount of an active pharmaceutical ingredient comprising levocetirizine or a pharmaceutically acceptable salt thereof, the solid oral dosage composition having a coating thereon capable of providing taste masking of the levocetirizine or pharmaceutically acceptable salt thereof.

The invention discloses a levocetirizine dihydrochloride granule and preparation and detection methods thereof. The specification of the levocetirizine dihydrochloride particle is 2.5 mg, and milk sugar is used as filling agent. The levocetirizine dihydrochloride granule dispenses with the process of disintegration of tablets and capsules in a human body, the degree of dispersion in the human bodyis superior to the tablets and the capsules, and the absorption is faster than the tablets, the capsules and dispersible tablets; and the flowability, the dispersibility and the adhesiveness are better than the dispersible tablets, the granule is convenient to take, the mouthfeel is easier to adjust, and the curative effect of the medicine can be guaranteed to be better played.

The invention belongs to the field of analytical chemistry, and particularly relates to a method for separating and determining levocetirizine hydrochloride and enantiomer thereof through an HPLC method. In the method, an adopted chromatographic column takes silica gel of which the surface is chemically bonded with beta-cyclodextrin as filler, elution is conducted through a mobile phase A and a mobile phase B, and detection is conducted by entering a detector; the mobile phase A is an inorganic salt buffer system, and the mobile phase B is organic solvent. The method is a reversed phase high performance liquid chromatography method, separation and determination of levocetirizine hydrochloride and the enantiomer thereof can be achieved simultaneously, excellent separation performance and durability are achieved, the method is simple, convenient, feasible, good in reproducibility, efficient and rapid, the analysis time is significantly shortened, the tailing factor and theoretical pedal number can both reach very good effects, the content of the enantiomer in levocetirizine hydrochloride can be effectively determined, and specificity is high.

The invention relates to a hydrochloric acid levocetirizine orally disintegrating tablet and a preparation method thereof. The hydrochloric acid levocetirizine orally disintegrating tablet is obtained by directly pressing principal medicine and accessories. The tablet of the invention can be dissolved fast in a mouth cavity and has no grit feeling and high biological availability, which takes effect fast and can have curative effect faster.

The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

The invention belongs to the field of analytical chemistry, and discloses a method for separately testing a levocetirizine hydrochloride intermediate and related substances of the levocetirizine hydrochloride intermediate by liquid chromatography. The method comprises the following steps: a chromatographic column taking octadecylsilane chemically bonded silica as a filler uses a certain proportion of buffer salt solution-organic phase as a mobile phase to quantificationally test the content of the levocetirizine hydrochloride intermediate and the content of the related substances of levocetirizine hydrochloride intermediate, so that the quality of the levocetirizine hydrochloride intermediate is effectively controlled, and the controllable quality of levocetirizine hydrochloride is ensured. The method is high in specificity and accuracy, and simple and convenient to operate.

The invention belongs to the field of medicinal preparations and discloses levocetirizine hydrochloride syrup and a preparation method. The levocetirizine hydrochloride syrup and the preparation method have the advantages that the bitter taste of the levocetirizine hydrochloride is covered, the adaptability of clinical medicines is improved, the treating effect is more ideal, and the preparation process is simple and is high in reliability.

The present invention describes a novel process for the preparation of levocetirizine and pharmaceutically acceptable acid addition salts thereof using diglycolic acid or derivatives thereof and new intermediates used in that process.

An exterior-applied levocetirizine hydrochloride for preventing and treating the anaphylaxia and inflammation without untoward effect is disclosed.

The invention relates to a levocetirizine preparation method and a levocetirizine dihydrochloride preparation method. Levocetirizine is prepared through a synthesis route shown in the specification, and levocetirizine dihydrochloride is prepared through hydrochlorinating the prepared levocetirizine to form a salt, and recrystallizing the salt. The preparation method which adopts cheap and easily available Pd-M/C to realize the catalytic oxidation of L-hydroxyzine as a catalyst in order to prepare levocetirizine realizes the high conversion rate of the substrate L-hydroxyzine and the high selectivity and high optical purity of the target product levocetirizine, and is an environmentally-friendly technology.

The invention provides levocetirizine hydrochloride oral drops good in taste and a preparation method thereof and belongs to the field of drug preparation. The levocetirizine hydrochloride oral drops are prepared from levocetirizine hydrochloride material, a solvent, a corrective, a preservative, a stabilizer, and a colorant, and the liquid medicine is quantitatively pumped out through a mechanical snap valve by using a quantitative dropper pump; the levocetirizine hydrochloride material has a concentration of 0.1-5 mg/ml in the drops herein. The liquid quantity of quantitative drops per snap is 0.1-2 ml. The levocetirizine hydrochloride oral drops are taken by an adult two to three times a day, 1-2 ml for each time. The levocetirizine hydrochloride oral quantitative drops are of a solvent type preparation and have the advantages medicine is distributed in a molecular form in liquid, may be quickly absorbed after administration, and acts fast; that dosage of the quantitative drops given by using the quantitative dropper pump is accurate, scientific and reasonable; the quantitative drops are sprayed directly into the mouth through a spray tube such that administration is greatly facilitated; the levocetirizine hydrochloride oral drops are good in taste and easy for a patient to accept.

The invention relates to a preparation for treating allergic rhinitis. The preparation is prepared by pressing a quick release layer and a sustained-release layer into bilayer tablets and coating, wherein the quick release layer consists of the following components in percentage by mass: 1 to 10 percent of levocetirizine hydrochloride, 1 to 15 percent of disintegrating agent, 0.5 to 3 percent of lubricating agent, 0 to 8 percent of adhesive and the balance of filler; the sustained-release layer consists of the following components in percentage by mass: 20 to 30 percent of pseudoephedrine hydrochloride, 50 to 60 percent of sustained-release framework material, 0.5 to 3 percent of lubricating agent, 0 to 8 percent of adhesive and the balance of filler; and the mass ratio of the levocetirizine hydrochloride to the pseudoephedrine hydrochloride is 1:48. The sustained-release tablets for treating the allergic rhinitis have bright and clean surfaces, and the release behavior of the main medicine pseudoephedrine hydrochloride of the sustained-release tablets has high consistency with that of American marketed medicine cetirizine hydrochloride and pseudoephedrine hydrochloride sustained-release tablets through detection; and the dissolution rate of the main medicine levocetirizine hydrochloride of the sustained-release tablets in 30 minutes is over 90 percent, so that the sustained-release preparation for treating the allergic rhinitis has high bioavailability, a good absorption effect, comprehensive and effective clinical curative effects, small side effects and ideal safety.

Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.

The present invention belongs to the field of pharmaceutical technology, and discloses one kind of orally taken compound levo-cetirizine pseudoephedrine preparation. The preparation has activity similar to that of compound cetirizine pseudoephedrine preparation and is single optical isomer with half reduced dosage and thus long effect and reduced side effect. The preparation may be taken by adult and children. The preparation process is also provided.

A naringin composition and preparations thereof are provided. The pharmaceutical composition comprises naringin and levocetirizine hydrochloride, and preferably, 27.5-275 mg of naringin and 1.25-12.5 mg of levocetirizine hydrochloride, where the preferred weight ratio of naringin to levocetirizine hydrochloride is 20:1. The pharmaceutical composition has good curative effects on cough and sputum production originating from various causes and on cough variant asthma. The efficacy of the pharmaceutical composition is obviously superior to that of naringin or levocetirizine hydrochloride that is used alone.

The invention belongs to the field of analytical chemistry, and particularly relates to a method for separating and determining levocetirizine hydrochloride and a genotoxic impurity E thereof by an HPLC method. A chromatographic column adopted in the method takes octadecyl bonded silica gel as a filler, a mixed mobile phase of potassium dihydrogen phosphate and methanol and/or acetonitrile is adopted for elution, and a product enters a detector for detection. The method is a reversed-phase high performance liquid chromatography method. Separation and detection of levocetirizine hydrochloride and genotoxic impurities E thereof can be realized at the same time; the method has excellent separation performance and durability, is simple, convenient and feasible, has good reproducibility, is efficient and rapid, can achieve very good effects on tailing factors and theoretical pedal numbers, can effectively determine the content of genotoxic impurities E in levocetirizine hydrochloride, and has strong specificity.

The invention provides a montelukast sodium and levocetirizine hydrochloride gastrointestinal capsule pharmaceutical composition, and can overcome the deficiency of the existing technology and effectively solve the problems of stability and the safety of clinical medication of the montelukast sodium and levocetirizine hydrochloride compound. The pharmaceutical composition achieves the purpose of simultaneous absorption of the montelukast sodium and levocetirizine hydrochloride in different parts, and can play a better synergistic therapeutic effect; through prescription screening and optimization, the montelukast sodium and levocetirizine hydrochloride gastrointestinal capsule pharmaceutical composition is provided; and the preparation ensures the stability of the drug during production and storage. A preparation method of the pharmaceutical composition is provided, and the method is simple and feasible, and applicable to industrial scale production through pilot-plant test.

The invention belongs to the field of medicine preparations, and particularly relates to a stable levocetirizine hydrochloride oral solution and a preparation method of same. Propionic acid is used asa preservative in the oral solution, volume percentage of the propionic acid being 0.05-0.15% in the oral solution. In the levocetirizine hydrochloride oral solution, the propionic acid is added, sothat the preservative effect as same as that of conventional preservatives is achieved, while toxicity is reduced and safety is increased. The levocetirizine hydrochloride oral solution has high stability and simple formula, is lower in toxicity of the preservative and has better safety. The preparation method is simple in operations and is easy to carry out industrially.

The invention provides a method for detecting related substances in a levocetirizine hydrochloride oral solution, belongs to the technical field of pharmaceutical analysis, and the method comprises the following steps: adopting a high performance liquid chromatography to detect the related substances in the levocetirizine hydrochloride oral solution, and calculating the content of related substances in the levocetirizine hydrochloride oral solution by using an external standard method. According to the method, acetonitrile and a monopotassium phosphate buffer solution are used as mobile phases, gradient elution is performed on a high performance liquid chromatograph, and parachlorobenzhydrol, parachlorobenzophenone, parachlorobenzhydryl piperazine, levocetirizine amide and p-hydroxybenzoic acid can be accurately and efficiently detected at a time under a liquid phase condition.

An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.